Emgality (galcanezumab)

pCPA File Number: 21690
Negotiation Status:
Under consideration for negotiation
Indication(s):
Prevention of migraine
Sponsor/Manufacturer:
Eli Lilly Canada Inc.
CADTH Project Number:
SR0693
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable